A Study to Evaluate Safety and Effectiveness of Cendakimab (CC-93538) in Participants With Moderate to Severe Atopic Dermatitis

NCT04800315 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

221

Enrollment

INDUSTRY

Sponsor class

Conditions

Dermatitis, Atopic
Eczema

Interventions

DRUG: CC-93538
OTHER: Placebo

Sponsor

Celgene